Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of KL1333 in Primary Mitochondrial Disease
NCT07514338Phase 2Recruiting
- Sponsor
- Pharming Group
- Start
- Jun 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of napazimone in primary mitochondrial disease (PMD), sponsored by Pharming Group. Primary endpoints: Adverse events at 48 weeks, Physical examination at 48 weeks and 7 more. Started Jun 2026; status: recruiting.
02
Drugs
napazimone
03
Conditions
primary mitochondrial disease (PMD)
Beyond the preview
Go deeper on NCT07514338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514338.